BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
May 17, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Dimebon latrepirdine: Phase III discontinued

Medivation said it will stop a pair of ongoing Phase III trials (CONSTELLATION and CONTACT) evaluating Dimebon in patients with moderate to severe AD. The Phase III CONCERT trial in patients with mild to moderate AD and the Phase III HORIZON trial to...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >